Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**cp-55,940** is a synthetic cannabinoid classified as a cyclohexylphenol derivative. It is a high-affinity, non-selective full agonist at both **cannabinoid receptor type 1 (CB1)** and **cannabinoid receptor type 2 (CB2)**, with a much greater potency than THC. In addition to its cannabinoid activity, cp-55,940 can upregulate **serotonin 5-HT2A receptor** expression[1][3][7][14]. Its pharmacological effects are mediated by interaction with neural and peripheral cannabinoid GPCRs, and it has been studied for roles in neurological and immunological models, including modulation of synaptic transmission, apoptosis in cell models, and behavioral assays.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cp-55,940.